Immunic presented key vidofludimus calcium data at the 41st congress of ectrims, highlighting its potential in multiple sclerosis

– vidofludimus calcium demonstrated statistically significant 24-week confirmed disability improvement in phase 2 calliper trial in progressive multiple sclerosis, with over two-fold probability over placebo in the overall study population and consistent effects across subtypes – – calliper data showed positive and consistent signals for slowing disability progression across disability endpoints, patient populations and subgroups without evidence of focal inflammation, reinforcing the drug's neuroprotective potential and promise to slow disease progression – – calliper data supports nurr1 activation as new mechanism to prevent neurodegeneration in multiple sclerosis – – long-term data from phase 2 emphasis trial in relapsing-remitting multiple sclerosis showed high rates of patients remaining free of 12- and 24-week confirmed disability worsening as well as low discontinuation rates and favorable long-term safety and tolerability – new york , sept. 25, 2025 /prnewswire/ --  immunic, inc.  (nasdaq: imux), a biotechnology company developing a clinical pipeline of orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases, today announced the presentation of key data in an oral and four poster presentations, including one late-breaking poster, at the 41st congress of the european committee for treatment and research in multiple sclerosis (ectrims), being held september 24-26, 2025 in barcelona, spain.
IMUX Ratings Summary
IMUX Quant Ranking